Article

Secukinumab Found Efficacious in Patients with Non-Radiographic Axial Spondyloarthritis

The PREVENT trial revealed that secukinumab demonstrated both efficacy and a favorable safety profile for patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Positive data from the PREVENT trial were announced this week surrounding the efficacy and safety of secukinumab (Cosentyx, Novartis) in patients with nr-axSpA.

At 52 weeks, the phase 2 trial met a primary endpoint, which was the proportion of patients achieving Assessment in SpondyloArthritis International Society 40% (ASAS40) response with secukinumab versus placebo 150 mg at weeks 16 and 52. The ASAS40 response may indicate clinically significant improvements in function, health-related quality of life, and work productivity, according to Healio Rheumatology. The trial also demonstrated a sustained response and a safety profile consistent with previous clinical trials, according to the press release.

According to Spondylitis Association of America, axSpA is a form of sypondyloarthritis in which the predominant symptom is back pain that persists for more than 3 months, and where radiographic sacroiliitis might not be present through the use of X-rays. There are approximately 1.7 million patients with nr-axSpA in the United States and Europe, according to the ERG Epidemiology Database.

Secukinumab has been examined for more than 5 years through clinical data for the use in ankylosing spondylitis, psoriatic arthritis, and psoriasis.

PREVENT is a 2-year randomized, double-blind, placebo-controlled trial that enrolled 555 patients with active nr-axSpA in order to evaluate the safety and efficacy of secukinumab in patients who had been taking at least 2 different non-steroidal anti-inflammatory drugs at the highest dosage up to 4 weeks prior to study start. Investigators defined active nr-axSpA as onset before 45 years of age, spinal pain rated as 40 or more out of 100 on a visual analog scale (VAS), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of 4 or more.

Positive 16-week PREVENT data were announced in mid-September. Novartis has submitted secukinumab to the European Medicines Agency for approval in nr-axSpA, which if approved would be the fourth indication for the drug. Novartis is currently planning an FDA submission.

"Non-radiographic axial spondyloarthritis is a chronic debilitating disease, which left untreated can have a significant impact on patients' quality of life," said Atul Deodhar, MD, professor of medicine and medical director of Rheumatology Clinics at Oregon Health & Science University, and an investigator in the secukinumab clinical trial program. "These positive results indicate a potential new treatment option to help patients experience relief from the signs and symptoms of their disease."

Related Videos
Abstract DNA molecule helix inside red blood drop
Woman experiencing pain related to recurrent pericarditis -- Image credit: Art_Photo | stock.adobe.com